FDA Clears Thermo Fisher's Multiplex Test for Simultaneous Detection of COVID-19, Flu, and RSV
Key Insights
Thermo Fisher Scientific (search) has received FDA 510(k) clearance for its TaqPath multiplex PCR test that simultaneously detects and differentiates between SARS-CoV-2 (search), Influenza A (search), Influenza B (search), and RSV in a single sample.
The new molecular diagnostic test delivers accurate results in approximately three hours, enabling healthcare providers to make rapid, informed treatment decisions during respiratory virus seasons.
The comprehensive testing solution includes a complete diagnostic workflow system, featuring the KingFisher Apex Dx system for sample preparation and the QuantStudio 5 Dx Real-Time PCR System for analysis.
Thermo Fisher Scientific (search) has achieved a significant advancement in respiratory virus diagnostics with FDA 510(k) clearance of its new multiplex molecular test. The Applied Biosystems (search) TaqPath COVID-19, Flu A, Flu B, RSV Select Panel enables healthcare providers to simultaneously screen for four major respiratory viruses from a single patient sample.
The innovative test addresses a critical challenge in respiratory medicine, where different viral infections often present with similar symptoms, making accurate diagnosis based on clinical presentation alone difficult. By enabling concurrent detection of SARS-CoV-2 (search), influenza A (search), influenza B (search), and respiratory syncytial virus (search) (RSV), the test significantly improves diagnostic efficiency and accuracy.
Clinical Impact and Performance
The TaqPath Select Panel delivers results in approximately three hours, providing clinicians with rapid, actionable information for patient management. This speed is particularly crucial during peak respiratory virus seasons when multiple pathogens circulate simultaneously. The test's ability to detect co-infections adds another valuable dimension to its diagnostic capabilities.
"As we enter the height of flu season and rates of RSV continue to climb, the clearance of this test provides crucial support to clinical communities as they look for reliable and efficient testing solutions," stated Rosy Lee, President of Genetic Sciences at Thermo Fisher Scientific (search).
Comprehensive Diagnostic Workflow
The FDA-cleared testing solution encompasses a complete diagnostic workflow system, featuring:
- The KingFisher Apex Dx system for automated sample preparation
- Applied Biosystems MagMAX Dx Viral/Pathogen NA Isolation Kit for high-quality nucleic acid extraction
- QuantStudio 5 Dx Real-Time PCR System for analysis
- TaqPath reagents including positive and negative controls, master mix, and an internal RNaseP endogenous control
This integrated system is designed to provide precise results while maintaining robust security features that meet diagnostic regulatory standards. The compact, cost-effective package makes it suitable for various clinical settings, including reference laboratories, clinical laboratories, and primary care facilities.
Applications and Implementation
The test is particularly valuable for:
- Reference and clinical laboratories requiring high-throughput testing capabilities
- Primary care settings managing respiratory infections
- Infectious disease surveillance programs tracking viral spread
The system's workflow simplicity and comprehensive design make it an efficient solution for healthcare facilities seeking to enhance their respiratory virus testing capabilities. By providing a single test for four common respiratory viruses, it streamlines diagnostic procedures and helps optimize resource utilization in clinical settings.